Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
Latest Information Update: 09 Jul 2026
At a glance
- Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
- Indications Hodgkin's disease; Malignant melanoma; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms POPSTAR
- Sponsors GSK
Most Recent Events
- 12 Nov 2025 Planned number of patients changed from 95 to 83.
- 12 Nov 2025 Planned End Date changed from 2 Jan 2032 to 13 Oct 2026.
- 12 Nov 2025 Planned primary completion date changed from 2 Jan 2032 to 13 Oct 2026.